2 completed, 1 withdrawn. 1 Phase 3.
| Phase | Trials | Status |
|---|---|---|
| Phase 3 | 1 | Completed 1 |
Follow Ming Hou: new trials by email
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| The Serum Lipid Profiles in ITP: a Retrospective Study ITP patients - Immune Thrombocytopenia | Completed | Ming Hou | 457 | 2018-01-01 | 2021-10-27 | |
| Recombinant Human Interleukin-11 Combination Low-dose Rituximab in Immune Thrombocytopenia rhIL-11 - Purpura, Thrombocytopenic, Idiopathic | Withdrawn | Ming Hou | 2011-03-01 | 2016-04-20 | ||
| Recombinant Human Thrombopoietin in Combination With Rituximab in Immune Thrombocytopenia (ITP) rhTPO in combination with Rituximab - Purpura, Idiopathic Thrombocytopenic Purpura | Phase 3 | Completed | Ming Hou | 91 | 2009-06-01 | 2016-04-20 |
Purpura, Thrombocytopenic, Idiopathic (3) · Purpura (1)
Rituximab (2) · Inosine Triphosphate (1) · Thrombopoietin (1) · oprelvekin (1)
China (3)
Hou Ming, Dr. (1)